Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2014

Open Access 01-12-2014 | Original research

Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT

Authors: Martin W Huellner, Timothy D Collen, Philipp Gut, Ralph Winterhalder, Chantal Pauli, Joachim Diebold, Burkhardt Seifert, Klaus Strobel, Patrick Veit-Haibach

Published in: EJNMMI Research | Issue 1/2014

Login to get access

Abstract

Background

The purpose of this study was to assess the relationship of CT-perfusion (CTP), 18F-FDG-PET/CT and histological parameters, and the possible added value of CTP to FDG-PET/CT in the initial staging of lung cancer.

Methods

Fifty-four consecutive patients (median age 65 years, 15 females, 39 males) with suspected lung cancer were evaluated prospectively by CT-perfusion scan and 18F-FDG-PET/CT scan. Overall, 46 tumors were identified. CTP parameters blood flow (BF), blood volume (BV), and mean transit time (MTT) of the tumor tissue were calculated. Intratumoral microvessel density (MVD) was assessed quantitatively. Differences in CTP parameters concerning tumor type, location, PET positivity of lymph nodes, TNM status, and UICC stage were analyzed. Spearman correlation analyses between CTP and 18F-FDG-PET/CT parameters (SUVmax, SUVmean, PETvol, and TLG), MVD, tumor size, and tumor stage were performed.

Results

The mean BF (mL/100 mL min-1), BV (mL/100 mL), and MTT (s) was 35.5, 8.4, and 14.2, respectively. The BF and BV were lower in tumors with PET-positive lymph nodes (p = 0.02). However, the CTP values were not significantly different among the N stages. The CTP values were not different, depending on tumor size and location. No significant correlation was found between CTP parameters and MVD.

Conclusions

Overall, the CTP information showed only little additional information for the initial staging compared with standard FDG-PET/CT. Low perfusion in lung tumors might possibly be associated with metabolically active regional lymph nodes. Apart from that, both CTP and 18F-FDG-PET/CT parameter sets may reflect different pathophysiological mechanisms in lung cancer.
Appendix
Available only for authorised users
Literature
1.
Ezzati M, Henley SJ, Lopez AD, Thun MJ: Role of smoking in global and regional cancer epidemiology: current patterns and data needs. Int J Cancer 2005, 116: 963–971. 10.1002/ijc.21100CrossRefPubMed
2.
Ezzati M, Lopez AD: Estimates of global mortality attributable to smoking in 2000. Lancet 2003, 362: 847–852. 10.1016/S0140-6736(03)14338-3CrossRefPubMed
3.
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61: 69–90. 10.3322/caac.20107CrossRefPubMed
4.
Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD: Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011, 365: 395–409.CrossRefPubMed
5.
Sone S, Li F, Yang ZG, Honda T, Maruyama Y, Takashima S, Hasegawa M, Kawakami S, Kubo K, Haniuda M, Yamanda T: Results of three-year mass screening programme for lung cancer using mobile low-dose spiral computed tomography scanner. Br J Cancer 2001, 84: 25–32. 10.1054/bjoc.2000.1531PubMedCentralCrossRefPubMed
6.
Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh GL, Clemens MA: Lung cancer screening with CT: Mayo Clinic experience. Radiology 2003, 226: 756–761. 10.1148/radiol.2263020036CrossRefPubMed
7.
Weidner N: Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat 1995, 36: 169–180. 10.1007/BF00666038CrossRefPubMed
8.
Aggarwal C, Somaiah N, Simon G: Antiangiogenic agents in the management of non-small cell lung cancer: where do we stand now and where are we headed? Cancer Biol Ther 2012, 13: 247–263. 10.4161/cbt.19594PubMedCentralCrossRefPubMed
9.
10.
Stevenson JP, Rosen M, Sun W, Gallagher M, Haller DG, Vaughn D, Giantonio B, Zimmer R, Petros WP, Stratford M, Chaplin D, Young SL, Schnall M, O’Dwyer PJ: Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003, 21: 4428–4438. 10.1200/JCO.2003.12.986CrossRefPubMed
11.
Willett CG, Boucher Y, di Tomaso E, Duda DG, Munn LL, Tong RT, Chung DC, Sahani DV, Kalva SP, Kozin SV, Mino M, Cohen KS, Scadden DT, Hartford AC, Fischman AJ, Clark JW, Ryan DP, Zhu AX, Blaszkowsky LS, Chen HX, Shellito PC, Lauwers GY, Jain RK: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10: 145–147. 10.1038/nm988PubMedCentralCrossRefPubMed
12.
Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B, Longo F, Catalano C, Passariello R: Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenetic chemotherapy: initial experience. Radiology 2011, 259: 574–582. 10.1148/radiol.11100600CrossRefPubMed
13.
Wang J, Wu N, Cham MD, Song Y: Tumor response in patients with advanced non-small cell lung cancer: perfusion CT evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol 2009, 193: 1090–1096. 10.2214/AJR.08.1367CrossRefPubMed
14.
Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, Jinnouchi M, Sakai S, Nakanishi Y, Honda H: Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology 2011, 261: 598–604. 10.1148/radiol.11101503CrossRefPubMed
15.
Sauter AW, Spira D, Schulze M, Pfannenberg C, Hetzel J, Reimold M, Klotz E, Claussen CD, Horger MS: Correlation between 18F-FDG PET/CT and volume perfusion CT in primary tumours and mediastinal lymph nodes of non-small-cell lung cancer. Eur J Nucl Med Mol Imaging 2013, 40: 677–684. 10.1007/s00259-012-2318-2CrossRefPubMed
16.
Sauter AW, Winterstein S, Spira D, Hetzel J, Schulze M, Mueller M, Pfannenberg C, Claussen CD, Klotz E, Hann von Weyhern C, Horger MS: Multifunctional profiling of non-small cell lung cancer using 18F-FDG PET/CT and volume perfusion CT. J Nucl Med 2012, 53: 521–529. 10.2967/jnumed.111.097865CrossRefPubMed
17.
Ng CS, Chandler AG, Wei W, Anderson EF, Herron DH, Charnsangavej C, Kurzrock R: Reproducibility of perfusion parameters obtained from perfusion CT in lung tumors. AJR Am J Roentgenol 2011, 197: 113–121. 10.2214/AJR.10.5404CrossRefPubMed
18.
Goh V, Halligan S, Gharpuray A, Wellsted D, Sundin J, Bartram CI: Quantitative assessment of colorectal cancer tumor vascular parameters by using perfusion CT: influence of tumor region of interest. Radiology 2008, 247: 726–732. 10.1148/radiol.2473070414CrossRefPubMed
19.
Rodgers J, Nicewander W: Thirteen ways to look at the correlation coefficient. JSTOR 1988, 41: 59–66.
20.
Goh V, Halligan S, Wellsted DM, Bartram CI: Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? A pilot study. Eur Radiol 2009, 19: 79–89. 10.1007/s00330-008-1128-1CrossRefPubMed
21.
Li SP, Makris A, Gogbashian A, Simcock IC, Stirling JJ, Goh V: Predicting response to neoadjuvant chemotherapy in primary breast cancer using volumetric helical perfusion computed tomography: a preliminary study. Eur Radiol 2012, 22: 1871–1880. 10.1007/s00330-012-2433-2CrossRefPubMed
22.
Park MS, Klotz E, Kim MJ, Song SY, Park SW, Cha SW, Lim JS, Seong J, Chung JB, Kim KW: Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009, 250: 110–117. 10.1148/radiol.2493080226CrossRefPubMed
23.
Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, Doot RK, Lawton TJ, Barlow WE, Kurland BF, Schubert EK, Mankoff DA: Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 2008, 26: 4449–4457. 10.1200/JCO.2007.15.4385PubMedCentralCrossRefPubMed
24.
Specht JM, Kurland BF, Montgomery SK, Dunnwald LK, Doot RK, Gralow JR, Ellis GK, Linden HM, Livingston RB, Allison KH, Schubert EK, Mankoff DA: Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer. Clin Cancer Res 2010, 16: 2803–2810. 10.1158/1078-0432.CCR-10-0026PubMedCentralCrossRefPubMed
25.
Tseng J, Dunnwald LK, Schubert EK, Link JM, Minoshima S, Muzi M, Mankoff DA: 18F-FDG kinetics in locally advanced breast cancer: correlation with tumor blood flow and changes in response to neoadjuvant chemotherapy. J Nucl Med 2004, 45: 1829–1837.PubMed
26.
Komar G, Kauhanen S, Liukko K, Seppanen M, Kajander S, Ovaska J, Nuutila P, Minn H: Decreased blood flow with increased metabolic activity: a novel sign of pancreatic tumor aggressiveness. Clin Cancer Res 2009, 15: 5511–5517. 10.1158/1078-0432.CCR-09-0414CrossRefPubMed
27.
Miles KA, Griffiths MR, Keith CJ: Blood flow-metabolic relationships are dependent on tumour size in non-small cell lung cancer: a study using quantitative contrast-enhanced computer tomography and positron emission tomography. Eur J Nucl Med Mol Imaging 2006, 33: 22–28.CrossRefPubMed
28.
Schmid-Bindert G, Henzler T, Chu TQ, Meyer M, Nance JW Jr, Schoepf UJ, Dinter DJ, Apfaltrer P, Krissak R, Manegold C, Schoenberg SO, Fink C: Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT? Eur Radiol 2012, 22: 93–103. 10.1007/s00330-011-2230-3CrossRefPubMed
29.
Ippolito D, Capraro C, Guerra L, De Ponti E, Messa C, Sironi S: Feasibility of perfusion CT technique integrated into conventional 18FDG/PET-CT studies in lung cancer patients: clinical staging and functional information in a single study. Eur J Nucl Med Mol Imaging 2012, 40(2):156–165.CrossRefPubMed
30.
Rajendran JG, Mankoff DA, O’Sullivan F, Peterson LM, Schwartz DL, Conrad EU, Spence AM, Muzi M, Farwell DG, Krohn KA: Hypoxia and glucose metabolism in malignant tumors: evaluation by [18 F]fluoromisonidazole and [18 F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004, 10: 2245–2252. 10.1158/1078-0432.CCR-0688-3CrossRefPubMed
31.
Padhani AR, Miles KA: Multiparametric imaging of tumor response to therapy. Radiology 2010, 256: 348–364. 10.1148/radiol.10091760CrossRefPubMed
32.
Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93: 266–276. 10.1093/jnci/93.4.266CrossRefPubMed
33.
Li M, Wu N, Zheng R, Liang Y, Liu Y, Zhang W, Li N, Zhao P: Primary tumor PET/CT [(1)(8)F]FDG uptake is an independent predictive factor for regional lymph node metastasis in patients with non-small cell lung cancer. Cancer Imaging 2013, 12: 566–572.PubMedCentralCrossRefPubMed
34.
Kiessling F, Boese J, Corvinus C, Ederle JR, Zuna I, Schoenberg SO, Brix G, Schmahl A, Tuengerthal S, Herth F, Kauczor HU, Essig M: Perfusion CT in patients with advanced bronchial carcinomas: a novel chance for characterization and treatment monitoring? Eur Radiol 2004, 14: 1226–1233.PubMed
35.
Cappabianca S, Porto A, Petrillo M, Greco B, Reginelli A, Ronza F, Setola F, Rossi G, Di Matteo A, Muto R, De Rimini ML, Piccolo S, Catalano M, Muto P, De Rosa N, Barra E, De Rosa I, Antinolfi F, Antinolfi G, Caputi M, Brunese L, Grassi R, Rotondo A: Preliminary study on the correlation between grading and histology of solitary pulmonary nodules and contrast enhancement and [18 F]fluorodeoxyglucose standardised uptake value after evaluation by dynamic multiphase CT and PET/CT. J Clin Pathol 2011, 64: 114–119. 10.1136/jcp.2010.076562PubMedCentralCrossRefPubMed
36.
Li Y, Yang ZG, Chen TW, Chen HJ, Sun JY, Lu YR: Peripheral lung carcinoma: correlation of angiogenesis and first-pass perfusion parameters of 64-detector row CT. Lung Cancer 2008, 61: 44–53. 10.1016/j.lungcan.2007.10.021CrossRefPubMed
37.
Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B, Tonini G: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 2004, 57: 591–597. 10.1136/jcp.2003.013508PubMedCentralCrossRefPubMed
38.
Kohler HH, Barth PJ, Siebel A, Gerharz EW, Bittinger A: Quantitative assessment of vascular surface density in renal cell carcinomas. Br J Urol 1996, 77: 650–654. 10.1046/j.1464-410X.1996.08544.xCrossRefPubMed
39.
Swensen SJ, Brown LR, Colby TV, Weaver AL, Midthun DE: Lung nodule enhancement at CT: prospective findings. Radiology 1996, 201: 447–455.CrossRefPubMed
40.
Tateishi U, Nishihara H, Watanabe S, Morikawa T, Abe K, Miyasaka K: Tumor angiogenesis and dynamic CT in lung adenocarcinoma: radiologic-pathologic correlation. J Comput Assist Tomogr 2001, 25: 23–27. 10.1097/00004728-200101000-00004CrossRefPubMed
41.
Goh V, Rodriguez-Justo M, Engledow A, Shastry M, Endozo R, Peck J, Meagher M, Taylor SA, Halligan S, Groves AM: Assessment of the metabolic flow phenotype of primary colorectal cancer: correlations with microvessel density are influenced by the histological scoring method. Eur Radiol 2012, 22: 1687–1692. 10.1007/s00330-012-2423-4CrossRefPubMed
42.
43.
Hansen S, Grabau DA, Rose C, Bak M, Sorensen FB: Angiogenesis in breast cancer: a comparative study of the observer variability of methods for determining microvessel density. Lab Invest 1998, 78: 1563–1573.PubMed
44.
Vermeulen PB, Libura M, Libura J, O’Neill PJ, van Dam P, Van Marck E, Van Oosterom AT, Dirix LY: Influence of investigator experience and microscopic field size on microvessel density in node-negative breast carcinoma. Breast Cancer Res Treat 1997, 42: 165–172. 10.1023/A:1005737524541CrossRefPubMed
45.
Ng QS, Goh V, Fichte H, Klotz E, Fernie P, Saunders MI, Hoskin PJ, Padhani AR: Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology 2006, 239: 547–553. 10.1148/radiol.2392050568CrossRefPubMed
46.
Ng QS, Goh V, Klotz E, Fichte H, Saunders MI, Hoskin PJ, Padhani AR: Quantitative assessment of lung cancer perfusion using MDCT: does measurement reproducibility improve with greater tumor volume coverage? AJR Am J Roentgenol 2006, 187: 1079–1084. 10.2214/AJR.05.0889CrossRefPubMed
Metadata
Title
Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT
Authors
Martin W Huellner
Timothy D Collen
Philipp Gut
Ralph Winterhalder
Chantal Pauli
Joachim Diebold
Burkhardt Seifert
Klaus Strobel
Patrick Veit-Haibach
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2014
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/2191-219X-4-6

Other articles of this Issue 1/2014

EJNMMI Research 1/2014 Go to the issue

Original research

Monitoring tumour response during chemo-radiotherapy: a parametric method using FDG-PET/CT images in patients with oesophageal cancer

Original research

U-SPECT-BioFluo: an integrated radionuclide, bioluminescence, and fluorescence imaging platform

Original research

Modification of intracellular glutathione status does not change the cardiac trapping of 64Cu(ATSM)

Original research

Potential of 99mTc-MIBI SPECT imaging for evaluating non-alcoholic steatohepatitis induced by methionine-choline-deficient diet in mice

Original research

Could 18 F-DPA-714 PET imaging be interesting to use in the early post-stroke period?

Original research

Labeling galectin-3 for the assessment of myocardial infarction in rats